Gerry R Boss

7981694, Jul 19, 2011

Jan 28, 2004

10/767251

Gerry R. Boss - La Jolla CA, US
Stephen B. Jones - San Diego CA, US
Jeffrey C. Chen - San Gabriel CA, US
Friederike von Lintig - San Diego CA, US
Stephanie Hoffman - Patatuma CA, US
Adam Kimmerly - San Diego CA, US
Joann Luu - San Jose CA, US
Matthew Christopher Mycroft - Sierra Madre CA, US

The Regents of the University of California - Oakland CA

G01N 33/543

436518, 436524, 436527, 436528, 436532

The invention is a method for the isolation of molecules of interest using tubes in which at least a portion of the inner walls of the tube are coated with microbeads that are coated with a capture reagent to bind the molecule of interest. The microbeads may be glass or polymer beads. The invention is a method and apparatus for preparation of the tubes for use in the method of the invention. The invention is a method for determining ratios of guanine nucleotides bound to guanine-nucleotide binding proteins.

8222242, Jul 17, 2012

Apr 10, 2008

12/595799

Gerry R. Boss - La Jolla CA, US
Vijay Sharma - Encinitas CA, US
Kate E. Broderick - San Diego CA, US

The Regents of the University of California - Oakland CA

A01N 55/02
A61K 31/555
C07B 47/00
C07D 487/22

514185, 540145

Compositions comprising nitrosyl-cobinamide are provided. Also provided are methods for treating hypertension, which comprise administering therapeutically effective amounts of nitrosyl-cobinamide. Also provided are methods for producing nitrosyl-cobinamide.

8431561, Apr 30, 2013

Jun 17, 2005

11/630049

Gerry Boss - La Jolla CA, US
Vijay Sharma - Encinitas CA, US
Kate E. Broderick - San Diego CA, US

The Regents of the University of California - Oakland CA

A61K 31/555
A61K 31/70

514186, 514 52

Methods for treating disease states in a subject caused or exacerbated by the presence of excess nitric oxide (NO) or excess cyanide are provided. Methods for alleviating the symptoms of a disease state in a subject caused or exacerbated by the presence of excess nitric oxide (NO) or excess cyanide in the subject are also provided. Pharmaceutical compositions comprising cobinamide and a pharmaceutically acceptable carrier are also provided.

20130005044, Jan 3, 2013

Mar 15, 2011

13/634703

Gerry Boss - La Jolla CA, US
Vijay Sharma - La Jolla CA, US
Matthew Brenner - Irvine CA, US
William Curt Blackledge - Carlsbad CA, US

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

G01N 21/76
C07F 15/06

436109, 540145

A method and devices analyze for the presence of cyanide in samples using colorimetric analysis of samples after contacting with cobinamide or monocyanocohinapmide.

57416354, Apr 21, 1998

Jan 30, 1996

8/593614

Gerry R. Boss - La Jolla CA
Abhijit Guha - Etobicoke, CA
Jurgen S. Scheele - Del Mar CA
Anthony J. Pawson - Toronto, CA

Mount Sinai Hospital Corporation - Toronto
The Regents of the University of California - Oakland CA

C07K 100
C12Q 100

435 4

The invention features methods for measuring the total amounts of G protein-bound GDP and GTP in mammalian cells and tissue. The method of the invention is advantageous over conventional methods in that the cells need not be exposed to phosphate-free growth conditions, which can adversely affect the accuracy of the GTP determination. Moreover, the method does not require exposure of the cells to radiolabelled phosphate in the growth medium. Standardized amounts of G protein-bound GDP and GTP are determined relative to non-nuclear cellular protein content or cellular DNA content, allowing comparison of results across different cell types. The method is particularly applicable to the detection of Ras protein bound GTP and GDP. The determination of Ras-bound GTP levels by the method of the invention provides a sensitive and accurate means of evaluating the role of Ras activation in cellular processes, such as cell proliferative disease, hormonal secretion, cellular differentiation, programmed cell death, cell cycle regulation, and protein trafficking. Treatment of abnormal processes can then more accurately targeted to the alteration of G protein activation.

20200276148, Sep 3, 2020

Apr 12, 2018

16/604510

- Boston MA, US
- Oakland CA, US
Anjali Nath - Boston MA, US
Calum MacRae - Wellesley Hills MA, US
Gerry Boss - La Jolla CA, US
Matt Brenner - Irvine CA, US
Sari Brenner Mahon - Irvine CA, US

A61K 31/282
A61P 39/02

The present application provides, inter alia, a compound of Formula (I): or a pharmaceutically acceptable salt thereof, and methods of use of the compound of Formula (I) for treatment and prevention of cyanide poisoning.